Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Diasunate Infant## (triplicate wtih different dosage form)

Diasunate Infant## (triplicate wtih different dosage form)

NAFDAC REG NO: A11-0098 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 15 November 2026 · synced automatically from official sources.
Produit
Diasunate Infant## (triplicate wtih different dosage form)
Numéro NAFDAC
A11-0098
Principe actif
Artesunate; Amodiaquine (Amodiaquine Hydrochloride)
Dosage
25 mg; 75 mg
Forme
Powder
Fabricant
Non répertorié
Déposant / Titulaire :
Emzor Pharmaceutical Industries Limited
Approuvé
29 Mar 2021
Statut
Inactive Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
28 Mar 2026
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Artesunate: uses, dosage and brands worldwide

What we found

  • Diasunate Infant## (triplicate wtih different dosage form) is on the NAFDAC register with an active registration (A11-0098). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Diasunate Infant## (triplicate wtih different dosage form)

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia. 25% Dextrose Injection also provides a minimal source of carbohydrate calories.

Comment le prendre et à quelle fréquence
  • When possible, glucose concentrations of greater than 12% should be administered by central vein to reduce the risk for phlebitis and thrombosis. 25% Dextrose Injection, USP is administered only by slow intravenous injection
  • The dosage and constant infusion rate of intravenous dextrose must be selected with caution, particularly in neonates and low birth weight
  • Infants, because of the increased risk of hyperglycemia/ hypoglycemia
  • In the neonate, an injection of 250 to 500 mg (1 to 2 mL)/kg/dose (5 to 10 mL of 25% dextrose in a 5 kg infant) is recommended to control acute symptomatic hypoglycemia (tremors, convulsions, etc.)
  • Larger or repeated single doses (up to 10 or 12 mL of 25% dextrose) may be required in severe cases or older infants
  • A specimen for blood glucose determination should be taken before injecting the dextrose
  • In such emergencies, dextrose should be administered promptly without awaiting pretreatment test results
  • Subsequent continuous intravenous infusion of 10% dextrose injection may be needed to stabilize blood glucose levels
  • Further treatment should be guided by evaluation of the underlying disorder
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS )
Talk to a doctor first if

A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present.

Warnings

25% Dextrose Injection, USP is hypertonic and may cause phlebitis and thrombosis at the site of injection. Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as loss of consciousness.

Effets secondaires possibles

Hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause mental confusion and/or loss of consciousness. Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

If you take too much

In the event of overdosage (hyperglycemia) during therapy, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS and PRECAUTIONS .)

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2022-12-09.

Label for Diasunate Infant## (triplicate wtih different dosage form), the active ingredient registered with NAFDAC.

Check your pack of Diasunate Infant## (triplicate wtih different dosage form)

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Diasunate Infant## (triplicate wtih different dosage form)

What is in Diasunate Infant## (triplicate wtih different dosage form)?

Diasunate Infant## (triplicate wtih different dosage form) contains Artesunate; Amodiaquine (Amodiaquine Hydrochloride) (25 mg; 75 mg), as powder, according to its NAFDAC registration record.

Is Diasunate Infant## (triplicate wtih different dosage form) registered with NAFDAC?

Yes. Diasunate Infant## (triplicate wtih different dosage form) is listed on the NAFDAC register under registration number A11-0098, and its registration is active as of 15 November 2026.

Has Diasunate Infant## (triplicate wtih different dosage form) been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Diasunate Infant## (triplicate wtih different dosage form) in our automatically synced alert list.

How can I check that my pack of Diasunate Infant## (triplicate wtih different dosage form) is genuine?

Run a free authenticity scan with the NAFDAC number A11-0098, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Diasunate Infant## (triplicate wtih different dosage form)?

Follow your prescription or the leaflet in your pack. The official label says: When possible, glucose concentrations of greater than 12% should be administered by central vein to reduce the risk for phlebitis and thrombosis. 25% Dextrose Injection, USP is administered only by slow intravenous injection. The dosage and constant infusion rate of intravenous dextrose must be selected with caution, particularly in neonates and low birth weight infants, becaus…

What is Diasunate Infant## (triplicate wtih different dosage form) used for?

25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurri (Summarised from the official U.S. FDA label for Diasunate Infant## (triplicate wtih different dosage form). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Diasunate Infant## (triplicate wtih different dosage form)? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.